



CURE & Yale OCR present the

Yale

BIOHAVEN

entrepreneurship series

2007 - 2008

Wednesday, October 24, 2007
BioRelix Pharmaceuticals, Inc.



Followed by networking, refreshments & wine bar

BioRelix is a new company developing antibiotics that target microbial RNA. As the Yale BioHaven Entrepreneurship Series opens its third season, two of the key players at BioRelix, founder Ronald Breaker, Ph.D., and interim CEO Ronald W Lennox, D. Phil., will explain the company's technology and business strategy.

Long recognized as reliable drugs, antibiotics have become a \$30 billion per year industry. But patents for many antibiotics will expire in the next few years, and all classes of antibiotics are encountering wide-spread resistance from the bacterial pathogens at which they are aimed.

BioRelix owns a world-wide license to develop and market RiboSwitch™-target antibiotics. "RiboSwitches™" are short stretches of messenger RNA that bind small metabolites and control genes that are essential for the survival of many disease-causing microbes. Each class of RiboSwitch™ could potentially serve as a novel antibacterial drug target.

In June of 2007, BioRelix raised almost \$26 million in a first funding round.

Speakers

Ronald Breaker, Ph.D.

Henry Ford II Professor in the Department of Molecular, Cellular and Developmental Biology, at Yale University and Founder, BioRelix Pharmaceuticals, Inc.

Ronald W. Lennox, D. Phil.

Partner, CHL Medical Partners and Interim CEO, BioRelix
Pharmaceuticals, Inc.

Wednesday, Oct 24, 2007

3:30 P.M. Registration

4:00 P.M. Seminar

5:00 P.M. Networking, Refreshments & Wine Bar

Location

The Anlyan Center auditorium, Yale Medical School.

Directions & Parking:

<http://info.med.yale.edu/maps/cab.html>

RSVP

Registration is free, but please RSVP in advance. E-mail to imalis@curenet.org or call the Yale
OCR main number: 203-785-6209.

Mark Your Calendar

The next seminar in the series, on **Nov 13, 2007**, features Vascular Insights.

**Series presented by CURE and the Yale Office of Cooperative Research, with support
from the Yale Entrepreneurial Society and the Yale Biotechnology & Pharmaceutical
Society**



Yale Biotechnology &
Pharmaceutical Society

Published by Connecticut United for Research Excellence

Copyright © 2007 Connecticut United for Research Excellence. All rights reserved.

Visit CURE at <http://curenet.org> and BioBus Educational Programs at <http://ctbiobus.org>

TELL A FRIEND

Powered by **IMN™**